# US 2012/0252840 A1 · Method of Treating Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252840 A1
- Document ID: US20120252840A1
- Status: Published application
- Kind: A1
- Application number: 13/438,964
- Filed: 2012-04-04
- Published: 2012-10-04
- Earliest claimed: 2011-04-04
- Assignees: Exelixis, Inc.
- Inventors: Dana T. Aftab; Frauke Schimmoller
- Web page: https://patentgrep.com/patent/US20120252840A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.

## Claims

### Claim 1

A method for treating melanoma, comprising administering to a patient in need of such treatment a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is halo;
R2 is halo;
R3 is (C1-C6)alkyl;
R4 is (C1-C6)alkyl; and
Q is CH or N.

### Claim 2 (depends on 1)

The method of claim 1, wherein the melanoma is ocular melanoma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ocular melanoma is choroidal or iris melanoma.

### Claim 4 (depends on 1)

The method of claim 1, wherein, the dual MET and VEGF modulator is a compound of Formula Ia:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is halo;
R2 is halo; and
Q is CH or N.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound of Formula I is Compound 1:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein Compound 1 is the (L)- or (D)-malate salt.

### Claim 7 (depends on 6)

The method of claim 6, wherein Compound 1 is in the crystalline N-1 form.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound of Formula I, I(a), or Compound 1, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent.

### Claim 9

A method for treating ocular melanoma comprising administering to a patient in need of such treatment Compound 1 or a pharmaceutically acceptable salt thereof.
